Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + IMRT in recurrent nasopharyngeal carcinoma
NCT03854838Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03854838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854838.